{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:45:04Z","timestamp":1790883904036,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amjmed.2026.05.024","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:08:27Z","timestamp":1779376107000},"page":"1480-1487.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of recombinant zoster vaccine (Shingrix) in US adults aged \u226550 years"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-5348","authenticated-orcid":false,"given":"Yihua","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajide","family":"Adekunle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2063-1876","authenticated-orcid":false,"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amjmed.2026.05.024_bib0001","first-page":"656","article-title":"Herpes zoster and postherpetic neuralgia: prevention and management","volume":"96","author":"Saguil","year":"2017","journal-title":"afp"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0002","article-title":"Shingles facts and stats","year":"2024","journal-title":"Shingles (Herpes Zoster)"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.024_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","article-title":"Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition","volume":"161","author":"Harvey","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: a systematic review and network meta-analysis","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.amjmed.2026.05.024_bib0005","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.05.024_bib0006","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0007","doi-asserted-by":"crossref","unstructured":"Anderson T.C., Masters N.B., Guo A., et al. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices \u2014 United States, 2022.","DOI":"10.1111\/ajt.16649"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.024_bib0008","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of Herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.024_bib0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted Herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.05.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz219","article-title":"A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of Herpes zoster and post-herpetic neuralgia","volume":"6","author":"Carpenter","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.amjmed.2026.05.024_bib0011","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamainternmed.2018.3200","article-title":"Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the recombinant adjuvanted zoster subunit vaccine","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.amjmed.2026.05.024_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-term protection against Herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.024_bib0013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/M23-2023","article-title":"Effectiveness of recombinant zoster vaccine against Herpes zoster in a real-world setting","volume":"177","author":"Zerbo","year":"2024","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2026.05.024_bib0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/infdis\/jiz652","article-title":"The epidemiology of Herpes zoster in immunocompetent, unvaccinated adults \u226550 years old: incidence, complications, hospitalization, mortality, and recurrence","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.amjmed.2026.05.024_bib0016","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of Herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0017","article-title":"Period life table, 2022, as used in the 2025 trustees report","year":"2025","journal-title":"Soc Secur Adm"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0018","article-title":"Overview of two economic models that assess the cost-effectiveness of herpes zoster vaccinations","author":"Leidner","year":"2017","journal-title":"Present at: Advis Comm Immun Pract (ACIP)"},{"issue":"15","key":"10.1016\/j.amjmed.2026.05.024_bib0019","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.vaccine.2022.03.006","article-title":"Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017\u20132021","volume":"40","author":"LaMori","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.amjmed.2026.05.024_bib0023","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1542\/peds.110.4.653","article-title":"Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis","volume":"110","author":"Zhou","year":"2002","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.amjmed.2026.05.024_bib0024","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2026.05.024_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00019053-200826020-00006","article-title":"Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness","volume":"26","author":"Prosser","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"16","key":"10.1016\/j.amjmed.2026.05.024_bib0026","first-page":"352","article-title":"Benefits from immunization during the vaccines for children program era - United States, 1994-2013","volume":"63","author":"Whitney","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.amjmed.2026.05.024_bib0027","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2011.607482","article-title":"Work and productivity loss related to herpes zoster","volume":"14","author":"Singhal","year":"2011","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.amjmed.2026.05.024_bib0028","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2018.12.034","article-title":"Trends in U.S. Community hospitalizations due to herpes zoster: 2001\u20132015","volume":"37","author":"Pham","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0029","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amjmed.2026.05.024_bib0030","article-title":"Vaccination Coverage among adults in the United States, National Health Interview Survey, 2022","year":"2025","journal-title":"AdultVaxView"},{"issue":"12","key":"10.1016\/j.amjmed.2026.05.024_bib0031","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of Herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.amjmed.2026.05.024_bib0032","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.2025.5013","article-title":"Herpes zoster vaccination and dementia occurrence","volume":"333","author":"Pomirchy","year":"2025","journal-title":"JAMA"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326004316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326004316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:13:34Z","timestamp":1790846014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326004316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0002934326004316"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of recombinant zoster vaccine (Shingrix) in US adults aged \u226550 years","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}